Irbesartan Hydrochlorothiazide Zentiva

Irbesartan, the active ingredient in Irbesartan Hydrochlorothiazide Zentiva, is an Angiotensin II receptor blocker (ARB) presented as a fixed‑dose oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients and works together with hydrochlorothiazide to improve blood‑pressure control.

GNH USA supplies Irbesartan Hydrochlorothiazide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is an antihypertensive combination that targets elevated blood pressure.

- Hypertension: lowers systolic and diastolic pressure in patients with essential hypertension, helping to reduce cardiovascular risk.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances such as low potassium - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia, especially when combined with potassium‑sparing agents - Angioedema or severe allergic reactions - Significant drops in blood pressure (hypotension)

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: ensure adequate control and avoid hypotension. - Renal function: assess baseline creatinine and eGFR, especially in patients with chronic kidney disease. - Electrolytes: check serum potassium and sodium levels regularly. - Diabetes: monitor glucose as thiazides may affect glycemic control. - Pregnancy and lactation: use only if potential benefit justifies potential risk; safety data are limited. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment - Potassium‑sparing diuretics or supplements (risk of hyperkalemia) - Lithium (increased lithium levels and toxicity) - ACE inhibitors or other ARBs (excessive renin‑angiotensin blockade) - NSAIDs (may reduce antihypertensive effect and impair renal function)

Moderate Interactions (Monitor Closely): - Other antihypertensives (additive blood‑pressure lowering) - CYP2C9 inhibitors such as fluconazole (may increase irbesartan levels) - Antidiabetic agents (thiazide‑induced hyperglycemia may require dose adjustment)